86 related articles for article (PubMed ID: 21571040)
1. Metabolite modulation of HeLa cell response to ENOX2 inhibitors EGCG and phenoxodiol.
Wu LY; De Luca T; Watanabe T; Morré DM; Morré DJ
Biochim Biophys Acta; 2011 Aug; 1810(8):784-9. PubMed ID: 21571040
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells.
De Luca T; Morré DM; Morré DJ
J Cell Biochem; 2010 Aug; 110(6):1504-11. PubMed ID: 20518072
[TBL] [Abstract][Full Text] [Related]
3. Downstream targets of altered sphingolipid metabolism in response to inhibition of ENOX2 by phenoxodiol.
De Luca T; Bosneaga E; Morré DM; Morré DJ
Biofactors; 2008; 34(3):253-60. PubMed ID: 19734127
[TBL] [Abstract][Full Text] [Related]
4. NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis.
De Luca T; Morré DM; Zhao H; Morré DJ
Biofactors; 2005; 25(1-4):43-60. PubMed ID: 16873929
[TBL] [Abstract][Full Text] [Related]
5. Mouse embryonic fibroblast cells from transgenic mice overexpressing tNOX exhibit an altered growth and drug response phenotype.
Yagiz K; Wu LY; Kuntz CP; James Morré D; Morré DM
J Cell Biochem; 2007 May; 101(2):295-306. PubMed ID: 17115410
[TBL] [Abstract][Full Text] [Related]
6. Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin.
Morré DJ; McClain N; Wu LY; Kelly G; Morré DM
Mol Biotechnol; 2009 May; 42(1):100-9. PubMed ID: 19156549
[TBL] [Abstract][Full Text] [Related]
7. Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture.
Morré DJ; Bridge A; Wu LY; Morré DM
Biochem Pharmacol; 2000 Oct; 60(7):937-46. PubMed ID: 10974202
[TBL] [Abstract][Full Text] [Related]
8. Catechin-vanilloid synergies with potential clinical applications in cancer.
Morré DM; Morré DJ
Rejuvenation Res; 2006; 9(1):45-55. PubMed ID: 16608395
[TBL] [Abstract][Full Text] [Related]
9. ENOX2 (or tNOX): a new and old molecule with cancer activity involved in tumor prevention and therapy.
Ronconi G; Lessiani G; Spinas E; Kritas SK; Caraffa Al; Saggini A; Antinolfi P; Pizzicannella J; Toniato E; Conti P
J Biol Regul Homeost Agents; 2016; 30(3):649-653. PubMed ID: 27655481
[TBL] [Abstract][Full Text] [Related]
10. tNOX is both necessary and sufficient as a cellular target for the anticancer actions of capsaicin and the green tea catechin (-)-epigallocatechin-3-gallate.
Chueh PJ; Wu LY; Morré DM; Morré DJ
Biofactors; 2004; 20(4):235-49. PubMed ID: 15706060
[TBL] [Abstract][Full Text] [Related]
11. Is the cancer protective effect correlated with growth inhibitions by green tea (-)-epigallocatechin gallate mediated through an antioxidant mechanism?
Cutter H; Wu LY; Kim C; Morré DJ; Morré DM
Cancer Lett; 2001 Jan; 162(2):149-54. PubMed ID: 11146219
[TBL] [Abstract][Full Text] [Related]
12. ENOX2 target for the anticancer isoflavone ME-143.
Morré DJ; Korty T; Meadows C; Ades LM; Morré DM
Oncol Res; 2014; 22(1):1-12. PubMed ID: 25700353
[TBL] [Abstract][Full Text] [Related]
13. Study of the combined effect of X-irradiation and epigallocatechin-gallate (a tea component) on the growth inhibition and induction of apoptosis in human cancer cell lines.
Baatout S; Jacquet P; Derradji H; Ooms D; Michaux A; Mergeay M
Oncol Rep; 2004 Jul; 12(1):159-67. PubMed ID: 15201978
[TBL] [Abstract][Full Text] [Related]
14. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells.
Herst PM; Petersen T; Jerram P; Baty J; Berridge MV
Biochem Pharmacol; 2007 Dec; 74(11):1587-95. PubMed ID: 17904534
[TBL] [Abstract][Full Text] [Related]
15. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma.
Nihal M; Ahmad N; Mukhtar H; Wood GS
Int J Cancer; 2005 Apr; 114(4):513-21. PubMed ID: 15609335
[TBL] [Abstract][Full Text] [Related]
16. ECTO-NOX target for the anticancer isoflavene phenoxodiol.
Morré DJ; Chueh PJ; Yagiz K; Balicki A; Kim C; Morré DM
Oncol Res; 2007; 16(7):299-312. PubMed ID: 17518268
[TBL] [Abstract][Full Text] [Related]
17. Antisense experiments demonstrate an exon 4 minus splice variant mRNA as the basis for expression of tNOX, a cancer-specific cell surface protein.
Tang X; Morré DJ; Morré DM
Oncol Res; 2007; 16(12):557-67. PubMed ID: 18351130
[TBL] [Abstract][Full Text] [Related]
18. 1Alpha,25-dihydroxyvitamin D3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase.
Kleuser B; Cuvillier O; Spiegel S
Cancer Res; 1998 May; 58(9):1817-24. PubMed ID: 9581819
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of phenoxodiol: from bench to clinic.
Alvero AB; Kelly M; Rossi P; Leiser A; Brown D; Rutherford T; Mor G
Future Oncol; 2008 Aug; 4(4):475-82. PubMed ID: 18684059
[TBL] [Abstract][Full Text] [Related]
20. Phenoxodiol: isoflavone analog with antineoplastic activity.
Choueiri TK; Wesolowski R; Mekhail TM
Curr Oncol Rep; 2006 Mar; 8(2):104-7. PubMed ID: 16507219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]